nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—BCHE—Cisplatin—testicular cancer	0.127	0.27	CbGbCtD
Mefloquine—ABCB1—Dactinomycin—testicular cancer	0.0561	0.119	CbGbCtD
Mefloquine—CYP3A4—Ifosfamide—testicular cancer	0.0397	0.0843	CbGbCtD
Mefloquine—CYP19A1—corpus luteum—testicular cancer	0.0388	0.213	CbGeAlD
Mefloquine—ABCB1—Vinblastine—testicular cancer	0.0351	0.0747	CbGbCtD
Mefloquine—CYP2D6—Vinblastine—testicular cancer	0.0331	0.0703	CbGbCtD
Mefloquine—CYP19A1—seminiferous tubule of testis—testicular cancer	0.0329	0.18	CbGeAlD
Mefloquine—ABCB1—Cisplatin—testicular cancer	0.0322	0.0684	CbGbCtD
Mefloquine—ABCB1—Etoposide—testicular cancer	0.0317	0.0673	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—testicular cancer	0.0216	0.0459	CbGbCtD
Mefloquine—CYP3A4—Vinblastine—testicular cancer	0.0211	0.0447	CbGbCtD
Mefloquine—ABCB1—Methotrexate—testicular cancer	0.0209	0.0444	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—testicular cancer	0.0203	0.0432	CbGbCtD
Mefloquine—CYP3A4—Etoposide—testicular cancer	0.019	0.0403	CbGbCtD
Mefloquine—CYP19A1—semen—testicular cancer	0.0182	0.0997	CbGeAlD
Mefloquine—HBA2—embryo—testicular cancer	0.0135	0.0738	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—testicular cancer	0.0129	0.0275	CbGbCtD
Mefloquine—HBA1—female gonad—testicular cancer	0.00809	0.0443	CbGeAlD
Mefloquine—HBA2—female gonad—testicular cancer	0.00743	0.0407	CbGeAlD
Mefloquine—HBA1—testis—testicular cancer	0.00718	0.0393	CbGeAlD
Mefloquine—HBA2—testis—testicular cancer	0.00659	0.0361	CbGeAlD
Mefloquine—HBA1—lymph node—testicular cancer	0.0052	0.0285	CbGeAlD
Mefloquine—HBA2—lymph node—testicular cancer	0.00478	0.0262	CbGeAlD
Mefloquine—ADORA2A—gonad—testicular cancer	0.00476	0.0261	CbGeAlD
Mefloquine—ADORA2A—testis—testicular cancer	0.00343	0.0188	CbGeAlD
Mefloquine—ADORA1—testis—testicular cancer	0.00296	0.0162	CbGeAlD
Mefloquine—ACHE—testis—testicular cancer	0.00294	0.0161	CbGeAlD
Mefloquine—CYP19A1—gonad—testicular cancer	0.00279	0.0153	CbGeAlD
Mefloquine—BCHE—seminal vesicle—testicular cancer	0.00278	0.0152	CbGeAlD
Mefloquine—CYP19A1—female gonad—testicular cancer	0.00226	0.0124	CbGeAlD
Mefloquine—ADORA1—lymph node—testicular cancer	0.00215	0.0118	CbGeAlD
Mefloquine—ACHE—lymph node—testicular cancer	0.00213	0.0117	CbGeAlD
Mefloquine—CYP19A1—testis—testicular cancer	0.00201	0.011	CbGeAlD
Mefloquine—CYP19A1—lymph node—testicular cancer	0.00146	0.00798	CbGeAlD
Mefloquine—BCHE—testis—testicular cancer	0.00145	0.00793	CbGeAlD
Mefloquine—ABCB1—embryo—testicular cancer	0.00141	0.00772	CbGeAlD
Mefloquine—ABCB1—seminal vesicle—testicular cancer	0.00132	0.00725	CbGeAlD
Mefloquine—CYP2D6—female gonad—testicular cancer	0.00108	0.00592	CbGeAlD
Mefloquine—BCHE—lymph node—testicular cancer	0.00105	0.00575	CbGeAlD
Mefloquine—CYP2D6—testis—testicular cancer	0.000959	0.00525	CbGeAlD
Mefloquine—ABCB1—gonad—testicular cancer	0.000957	0.00524	CbGeAlD
Mefloquine—ABCB1—female gonad—testicular cancer	0.000777	0.00426	CbGeAlD
Mefloquine—ABCB1—testis—testicular cancer	0.00069	0.00378	CbGeAlD
Mefloquine—ABCB1—lymph node—testicular cancer	0.0005	0.00274	CbGeAlD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00038	0.0011	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—testicular cancer	0.00038	0.0011	CcSEcCtD
Mefloquine—Renal failure—Methotrexate—testicular cancer	0.000377	0.00109	CcSEcCtD
Mefloquine—Asthenia—Ifosfamide—testicular cancer	0.000371	0.00107	CcSEcCtD
Mefloquine—Sweating—Methotrexate—testicular cancer	0.000368	0.00106	CcSEcCtD
Mefloquine—Feeling abnormal—Cisplatin—testicular cancer	0.000368	0.00106	CcSEcCtD
Mefloquine—Paraesthesia—Etoposide—testicular cancer	0.000367	0.00106	CcSEcCtD
Mefloquine—Pruritus—Ifosfamide—testicular cancer	0.000366	0.00106	CcSEcCtD
Mefloquine—Dyspnoea—Etoposide—testicular cancer	0.000364	0.00105	CcSEcCtD
Mefloquine—Somnolence—Etoposide—testicular cancer	0.000363	0.00105	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—testicular cancer	0.000363	0.00105	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—testicular cancer	0.000361	0.00104	CcSEcCtD
Mefloquine—Nausea—Bleomycin—testicular cancer	0.00036	0.00104	CcSEcCtD
Mefloquine—Vomiting—Dactinomycin—testicular cancer	0.000359	0.00104	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—testicular cancer	0.000358	0.00103	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000356	0.00103	CcSEcCtD
Mefloquine—Rash—Dactinomycin—testicular cancer	0.000356	0.00103	CcSEcCtD
Mefloquine—Decreased appetite—Etoposide—testicular cancer	0.000355	0.00102	CcSEcCtD
Mefloquine—Diarrhoea—Ifosfamide—testicular cancer	0.000354	0.00102	CcSEcCtD
Mefloquine—Renal failure—Epirubicin—testicular cancer	0.000353	0.00102	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000353	0.00102	CcSEcCtD
Mefloquine—Body temperature increased—Cisplatin—testicular cancer	0.000353	0.00102	CcSEcCtD
Mefloquine—Fatigue—Etoposide—testicular cancer	0.000352	0.00102	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000352	0.00102	CcSEcCtD
Mefloquine—Sweating—Epirubicin—testicular cancer	0.000344	0.000993	CcSEcCtD
Mefloquine—Dizziness—Ifosfamide—testicular cancer	0.000342	0.000987	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—testicular cancer	0.00034	0.00098	CcSEcCtD
Mefloquine—Feeling abnormal—Etoposide—testicular cancer	0.000337	0.000971	CcSEcCtD
Mefloquine—Nausea—Dactinomycin—testicular cancer	0.000335	0.000967	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—testicular cancer	0.000335	0.000967	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—testicular cancer	0.000334	0.000964	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—testicular cancer	0.000334	0.000964	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—testicular cancer	0.000332	0.000958	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000329	0.00095	CcSEcCtD
Mefloquine—Vomiting—Ifosfamide—testicular cancer	0.000329	0.000949	CcSEcCtD
Mefloquine—Hypersensitivity—Cisplatin—testicular cancer	0.000329	0.000948	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—testicular cancer	0.000328	0.000947	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—testicular cancer	0.000327	0.000942	CcSEcCtD
Mefloquine—Rash—Ifosfamide—testicular cancer	0.000326	0.000941	CcSEcCtD
Mefloquine—Dermatitis—Ifosfamide—testicular cancer	0.000326	0.00094	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—testicular cancer	0.000326	0.00094	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000326	0.00094	CcSEcCtD
Mefloquine—Urticaria—Etoposide—testicular cancer	0.000325	0.000936	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—testicular cancer	0.000323	0.000932	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—testicular cancer	0.000323	0.000932	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—testicular cancer	0.000322	0.000929	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—testicular cancer	0.000321	0.000927	CcSEcCtD
Mefloquine—Asthenia—Cisplatin—testicular cancer	0.00032	0.000923	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—testicular cancer	0.00032	0.000922	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—testicular cancer	0.000319	0.000919	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—testicular cancer	0.000317	0.000914	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000314	0.000907	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—testicular cancer	0.000313	0.000902	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—testicular cancer	0.000311	0.000896	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—testicular cancer	0.000311	0.000896	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—testicular cancer	0.00031	0.000895	CcSEcCtD
Mefloquine—Chills—Methotrexate—testicular cancer	0.000309	0.000892	CcSEcCtD
Mefloquine—Nausea—Ifosfamide—testicular cancer	0.000307	0.000887	CcSEcCtD
Mefloquine—Diarrhoea—Cisplatin—testicular cancer	0.000305	0.00088	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—testicular cancer	0.000305	0.000879	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—testicular cancer	0.000304	0.000878	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—testicular cancer	0.000304	0.000876	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—testicular cancer	0.000302	0.000871	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—testicular cancer	0.000301	0.000869	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—testicular cancer	0.000301	0.000868	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—testicular cancer	0.000301	0.000867	CcSEcCtD
Mefloquine—Erythema—Methotrexate—testicular cancer	0.0003	0.000865	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—testicular cancer	0.0003	0.000865	CcSEcCtD
Mefloquine—Flushing—Epirubicin—testicular cancer	0.000299	0.000863	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—testicular cancer	0.000299	0.000863	CcSEcCtD
Mefloquine—Asthenia—Etoposide—testicular cancer	0.000293	0.000846	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000293	0.000846	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—testicular cancer	0.000293	0.000844	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—testicular cancer	0.000291	0.000838	CcSEcCtD
Mefloquine—Chills—Epirubicin—testicular cancer	0.000289	0.000835	CcSEcCtD
Mefloquine—Pruritus—Etoposide—testicular cancer	0.000289	0.000834	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—testicular cancer	0.000287	0.000829	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—testicular cancer	0.000285	0.000822	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—testicular cancer	0.000284	0.000818	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—testicular cancer	0.000283	0.000815	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—testicular cancer	0.000282	0.000815	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—testicular cancer	0.000282	0.000814	CcSEcCtD
Mefloquine—Rash—Cisplatin—testicular cancer	0.000281	0.000811	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—testicular cancer	0.000281	0.000811	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—testicular cancer	0.000281	0.00081	CcSEcCtD
Mefloquine—Erythema—Epirubicin—testicular cancer	0.000281	0.00081	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—testicular cancer	0.00028	0.000807	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—testicular cancer	0.000279	0.000804	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—testicular cancer	0.000278	0.000803	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—testicular cancer	0.000278	0.000802	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—testicular cancer	0.000277	0.000799	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—testicular cancer	0.000277	0.000799	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—testicular cancer	0.000271	0.000781	CcSEcCtD
Mefloquine—Malaise—Methotrexate—testicular cancer	0.00027	0.00078	CcSEcCtD
Mefloquine—Dizziness—Etoposide—testicular cancer	0.00027	0.00078	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—testicular cancer	0.00027	0.000778	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—testicular cancer	0.000269	0.000777	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000269	0.000776	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—testicular cancer	0.000268	0.000774	CcSEcCtD
Mefloquine—Chills—Doxorubicin—testicular cancer	0.000268	0.000772	CcSEcCtD
Mefloquine—Nausea—Cisplatin—testicular cancer	0.000265	0.000764	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—testicular cancer	0.000265	0.000763	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—testicular cancer	0.000264	0.00076	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—testicular cancer	0.000261	0.000754	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—testicular cancer	0.00026	0.000751	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—testicular cancer	0.00026	0.00075	CcSEcCtD
Mefloquine—Vomiting—Etoposide—testicular cancer	0.00026	0.000749	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—testicular cancer	0.00026	0.000749	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—testicular cancer	0.00026	0.000749	CcSEcCtD
Mefloquine—Agitation—Epirubicin—testicular cancer	0.000258	0.000744	CcSEcCtD
Mefloquine—Rash—Etoposide—testicular cancer	0.000258	0.000743	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—testicular cancer	0.000257	0.000743	CcSEcCtD
Mefloquine—Headache—Etoposide—testicular cancer	0.000256	0.000738	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—testicular cancer	0.000255	0.000737	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—testicular cancer	0.000255	0.000737	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—testicular cancer	0.000255	0.000737	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000254	0.000731	CcSEcCtD
Mefloquine—Malaise—Epirubicin—testicular cancer	0.000253	0.00073	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—testicular cancer	0.000252	0.000728	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—testicular cancer	0.000252	0.000727	CcSEcCtD
Mefloquine—Syncope—Epirubicin—testicular cancer	0.000252	0.000726	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—testicular cancer	0.000251	0.000725	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—testicular cancer	0.00025	0.00072	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—testicular cancer	0.000248	0.000715	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—testicular cancer	0.000247	0.000712	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—testicular cancer	0.000247	0.000712	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—testicular cancer	0.000245	0.000706	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—testicular cancer	0.000245	0.000706	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—testicular cancer	0.000243	0.000701	CcSEcCtD
Mefloquine—Nausea—Etoposide—testicular cancer	0.000243	0.0007	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—testicular cancer	0.000242	0.000699	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000241	0.000695	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—testicular cancer	0.00024	0.000692	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—testicular cancer	0.00024	0.000691	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—testicular cancer	0.000239	0.000689	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—testicular cancer	0.000239	0.000689	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—testicular cancer	0.000239	0.000689	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—testicular cancer	0.000239	0.000688	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—testicular cancer	0.000238	0.000687	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—testicular cancer	0.000238	0.000686	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000237	0.000685	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—testicular cancer	0.000237	0.000683	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—testicular cancer	0.000236	0.000681	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—testicular cancer	0.000234	0.000676	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—testicular cancer	0.000233	0.000673	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—testicular cancer	0.000233	0.000672	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—testicular cancer	0.000232	0.000671	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—testicular cancer	0.000231	0.000666	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—testicular cancer	0.000229	0.000662	CcSEcCtD
Mefloquine—Oedema—Epirubicin—testicular cancer	0.000229	0.000661	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—testicular cancer	0.000229	0.000661	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—testicular cancer	0.000229	0.00066	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—testicular cancer	0.000228	0.000658	CcSEcCtD
Mefloquine—Shock—Epirubicin—testicular cancer	0.000225	0.00065	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—testicular cancer	0.000225	0.000649	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—testicular cancer	0.000225	0.000648	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—testicular cancer	0.000224	0.000647	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—testicular cancer	0.000224	0.000647	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—testicular cancer	0.000224	0.000645	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000223	0.000643	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—testicular cancer	0.000222	0.000642	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—testicular cancer	0.000221	0.000639	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—testicular cancer	0.000221	0.000639	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—testicular cancer	0.000221	0.000638	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—testicular cancer	0.000221	0.000638	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—testicular cancer	0.000221	0.000638	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—testicular cancer	0.00022	0.000636	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—testicular cancer	0.00022	0.000634	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00022	0.000633	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—testicular cancer	0.000218	0.00063	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—testicular cancer	0.000218	0.00063	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—testicular cancer	0.000218	0.000628	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—testicular cancer	0.000215	0.000622	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—testicular cancer	0.000214	0.000617	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—testicular cancer	0.000214	0.000616	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—testicular cancer	0.000213	0.000614	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000212	0.000611	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—testicular cancer	0.000212	0.000611	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000211	0.00061	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—testicular cancer	0.000211	0.000609	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000209	0.000602	CcSEcCtD
Mefloquine—Shock—Doxorubicin—testicular cancer	0.000209	0.000602	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—testicular cancer	0.000208	0.0006	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000208	0.000599	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—testicular cancer	0.000207	0.000598	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—testicular cancer	0.000207	0.000597	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—testicular cancer	0.000206	0.000594	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—testicular cancer	0.000206	0.000593	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000205	0.000591	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—testicular cancer	0.000204	0.000589	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—testicular cancer	0.000204	0.000587	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—testicular cancer	0.000202	0.000582	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—testicular cancer	0.000202	0.000582	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—testicular cancer	0.0002	0.000577	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—testicular cancer	0.000199	0.000574	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—testicular cancer	0.000198	0.000571	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000198	0.00057	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—testicular cancer	0.000197	0.00057	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—testicular cancer	0.000194	0.000561	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—testicular cancer	0.000193	0.000558	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—testicular cancer	0.000193	0.000558	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000193	0.000557	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—testicular cancer	0.000192	0.000553	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—testicular cancer	0.00019	0.000549	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—testicular cancer	0.000189	0.000545	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—testicular cancer	0.000189	0.000545	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—testicular cancer	0.000188	0.000544	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000187	0.00054	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—testicular cancer	0.000187	0.000538	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—testicular cancer	0.000184	0.000531	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000183	0.000528	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—testicular cancer	0.000183	0.000527	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—testicular cancer	0.000182	0.000525	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—testicular cancer	0.000181	0.000522	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—testicular cancer	0.000181	0.000522	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—testicular cancer	0.00018	0.00052	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—testicular cancer	0.000176	0.000507	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—testicular cancer	0.000175	0.000504	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000173	0.0005	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—testicular cancer	0.000173	0.0005	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—testicular cancer	0.000169	0.000487	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—testicular cancer	0.000168	0.000486	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—testicular cancer	0.000168	0.000483	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—testicular cancer	0.000168	0.000483	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—testicular cancer	0.000167	0.000483	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—testicular cancer	0.000164	0.000474	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—testicular cancer	0.000162	0.000467	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—testicular cancer	0.000162	0.000467	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—testicular cancer	0.000157	0.000452	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—testicular cancer	0.000156	0.00045	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—testicular cancer	0.000156	0.000449	CcSEcCtD
Mefloquine—Rash—Methotrexate—testicular cancer	0.000154	0.000445	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—testicular cancer	0.000154	0.000445	CcSEcCtD
Mefloquine—Headache—Methotrexate—testicular cancer	0.000153	0.000442	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—testicular cancer	0.000152	0.000439	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—testicular cancer	0.000151	0.000437	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—testicular cancer	0.00015	0.000433	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—testicular cancer	0.000146	0.00042	CcSEcCtD
Mefloquine—Nausea—Methotrexate—testicular cancer	0.000145	0.000419	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—testicular cancer	0.000145	0.000418	CcSEcCtD
Mefloquine—Rash—Epirubicin—testicular cancer	0.000144	0.000417	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—testicular cancer	0.000144	0.000416	CcSEcCtD
Mefloquine—Headache—Epirubicin—testicular cancer	0.000144	0.000414	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—testicular cancer	0.00014	0.000404	CcSEcCtD
Mefloquine—Nausea—Epirubicin—testicular cancer	0.000136	0.000392	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—testicular cancer	0.000135	0.000389	CcSEcCtD
Mefloquine—Rash—Doxorubicin—testicular cancer	0.000134	0.000385	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—testicular cancer	0.000134	0.000385	CcSEcCtD
Mefloquine—Headache—Doxorubicin—testicular cancer	0.000133	0.000383	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—testicular cancer	0.000126	0.000363	CcSEcCtD
